Hi GC, apart from the triple validation of NNZ-2591 as a “pipeline-in-a-drug” a positive Angelman Syndrome trial result would bring, the potential patient population is 2.5X larger than Pitt Hopkins so I’m wondering if that will have any bearing on the size of SP reaction post results readout.
The numbers below are from an older presentation, but it was the last time they were all listed on the same page.
Whilst the SP has been doing my head in since the PH results, I’m just happy that we’re above $20.00 as the games around this price point were manifold for some considerable length of time.
Hi GC, apart from the triple validation of NNZ-2591 as a...
-
- There are more pages in this discussion • 1,148 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |